Advertisement
Australia markets closed

  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     

  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     

  • AUD/USD

    0.6612
    +0.0040 (+0.61%)
     

  • OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD

    2,310.10
    +0.50 (+0.02%)
     

  • Bitcoin AUD

    96,951.94
    +1,602.86 (+1.68%)
     

  • CMC Crypto 200

    1,328.70
    +51.72 (+4.05%)
     

  • AUD/EUR

    0.6140
    +0.0020 (+0.33%)
     

  • AUD/NZD

    1.0992
    -0.0017 (-0.16%)
     

  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     

  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

iRhythm Technologies to Report First Quarter 2021 Financial Results on May 6, 2021

iRhythm
·1-min read

SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the first quarter 2021 after the close of trading on Thursday, May 6, 2021. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the “Investors” section of the company’s website at: www.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Investor Relations Contact
Leigh Salvo
(415) 937-5404
investors@irhythmtech.com

Media Contact
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com